Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib combinations in endometrial cancer
NCT02725268Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of sapanisertib in endometrial cancer (EC), sponsored by Millennium Pharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
sapanisertib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02725268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725268.